China Universal Asset Management Co., Ltd. Kiniksa Pharmaceuticals, Ltd. Transaction History

China Universal Asset Management Co., Ltd.

$893 Million
Q3 2024

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 29, 2024	BUY	$17.63 - $21.74 $63,661 - $78,503	3,611 Added 88.14%	7,708 $152,000
Q4 2023 May 21, 2024	SELL	$14.37 - $19.07 $51,890 - $68,861	-3,611 Reduced 46.85%	4,097 $71,000
Q4 2023 Jan 23, 2024	BUY	$14.37 - $19.07 $45,782 - $60,757	3,186 Added 349.73%	4,097 $72,000
Q3 2023 May 21, 2024	BUY	$13.62 - $20.2 $6,169 - $9,150	453 Added 98.91%	911 $15,000
Q3 2023 Oct 30, 2023	BUY	$13.62 - $20.2 $6,169 - $9,150	453 Added 98.91%	911 $16,000
Q2 2023 May 21, 2024	SELL	$10.44 - $16.48 $104 - $164	-10 Reduced 2.14%	458 $6,000
Q2 2023 Jul 27, 2023	SELL	$10.44 - $16.48 $104 - $164	-10 Reduced 2.14%	458 $6,000
Q1 2023 May 21, 2024	BUY	$10.7 - $15.79 $1,251 - $1,847	117 Added 33.33%	468 $5,000
Q1 2023 Apr 27, 2023	BUY	$10.7 - $15.79 $1,251 - $1,847	117 Added 33.33%	468 $5,000
Q4 2022 May 21, 2024	SELL	$11.42 - $17.05 $84,016 - $125,436	-7,357 Reduced 95.45%	351 $5,000
Q4 2022 Jan 31, 2023	BUY	$11.42 - $17.05 $319 - $477	28 Added 8.67%	351 $5,000
Q3 2022 Oct 21, 2022	BUY	$9.76 - $13.41 $3,152 - $4,331	323 New	323 $4,000

Others Institutions Holding KNSA

# of Institutions

Shares Held

1.95M

Call Options Held

Put Options Held

Pictet Asset Management Sa Geneva 73, V8

1.52M
Shares

$33.1 Million
0.03% of portfolio
Spearhead Capital Advisors, LLC Wellington, FL

203K
Shares

$4.42 Million
2.82% of portfolio
Harbor Capital Advisors, Inc.

97.5K
Shares

$2.13 Million
0.11% of portfolio
Putnam Investments LLC Boston, MA

39.5K
Shares

$860,794
0.0% of portfolio
Birchview Capital, LP Burlington, VT

30K
Shares

$654,000
0.69% of portfolio

View Full List

About Kiniksa Pharmaceuticals, Ltd.

Ticker KNSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,470,400
Market Cap $751M
Description
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...

More about KNSA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.

Account